Investigating CAR-T Efficacy Limitations in Chronic Lymphocytic Leukemia
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
Latest Features
LATEST ARTICLES
Navigating COVID-19: Self-Care Strategies for Oncology Professionals
A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results.
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Social Workers Are Underutilized in Oncologic Pain Management
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
No Solid Evidence to Support GEP Testing in Thin Melanoma
Most studies that have looked at 31-GEP testing in melanoma have been retrospective or prospective, and did not involve a comparator group.
Neoadjuvant Nivolumab Appears Promising in Merkel Cell Carcinoma
A small phase 1/2 study shows high pCR rates.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Radiation Therapy for Hematologic Cancers During the COVID-19 Pandemic
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
Tocilizumab Shows Benefit in a Patient With COVID-19 and Multiple Myeloma
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
PSA and Prostate Cancer Mortality: What’s the Link?
Has PSA screening led to overdiagnosis and overtreatment of a condition that may not actually cause any symptoms or lead to death?
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Ipilimumab May Help Some Patients With Prostate Cancer—Even Those With Low TMB
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Want to read more?
Please login or register first to view this content.
